Market Challenges And Opportunities

Low adherence to guidelines in sepsis care puts patients at risk

Low adherence to guidelines in sepsis care puts patients at risk and is expected to hinder market growth over the forecast period. For instance, on September 22, 2022, according to bioMérieux, a company in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsis Trust, an internationally renowned charity, released new survey data that was commissioned among 368 doctors across six European countries stated that sepsis is a life-threatening condition in which the body’s response to infection causes organ damage. Every year in Europe, more than 3.4 million people develop sepsis, and 700,000 of them do not survive.

Early recognition and rapid diagnosis are essential for early patient management. Any delay in starting appropriate treatment is associated with increased mortality. A set of evidence-based clinical practices, known as sepsis bundles, have been defined internationally. The routine implementation of these bundles by clinicians can greatly improve outcomes for patients with sepsis.

Key players focusing on developing awareness programs and advanced products with safety and cost-effective treatment would help to drive market growth over the forecast period.